60–130 mg/day (prostate); 2 g/day of phytosterols for cholesterol.
⏱ 3 min read
Beta-sitosterol is the most abundant phytosterol in most vegetable oils, nuts, seeds, and legumes; it is a plant sterol with a chemical structure very similar to that of human cholesterol, an analogy that is the basis of its best-known mechanism of action: competition with dietary cholesterol for intestinal absorption, which significantly reduces the absorption of exogenous cholesterol and, secondarily, plasma LDL levels; although beta-sitosterol is one of the main components of the phytosterol family (with other members such as campesterol and stigmasterol), it has also been studied in isolation for specific indications other than simple lipid modulation.
The most specific clinical indication for isolated beta-sitosterol (as opposed to the phytosterol mixture used mainly for cholesterol) is mild to moderate benign prostatic hyperplasia: several randomized trials have documented significant improvements in symptom scales (IPSS), peak urinary flow, and post-void residual volume at doses of 60-130 milligrams per day of beta-sitosterol for 4-6 months.
A Cochrane review published in 1999 with 4 trials and 519 patients confirmed the significant efficacy of beta-sitosterol in benign prostatic hyperplasia, with modest but clinically relevant effect sizes and a tolerability profile favorable compared with specific drugs such as alpha-blockers (terazosin, doxazosin, tamsulosin); these data position beta-sitosterol as a reasonable phytotherapy option for mild symptomatic benign prostatic hyperplasia, alongside Serenoa repens (saw palmetto), Pygeum africanum, nettle root, and other traditional interventions.
As part of the dietary phytosterol mixture, beta-sitosterol contributes to LDL cholesterol reduction through the mechanism of competition with intestinal cholesterol absorption; daily intakes of 2-3 grams of total phytosterols (including beta-sitosterol as the main component) produce reductions of 10-15 percent in plasma LDL, a relevant magnitude achievable with commercial fortified products (margarines, drinkable yogurts with added phytosterols) or with diets naturally rich in unrefined vegetable oils, nuts, and seeds.
Some small studies have documented immunomodulatory effects with supplementation at low doses (20-40 mg/day) in people with recurrent respiratory infections or suboptimal immune function, an indication with modest clinical support but consistent with preclinical data on lymphocyte modulation and cellular immune response.
The doses for benign prostatic hyperplasia are 60-130 milligrams per day divided into 2-3 doses with or without food; for cholesterol reduction as part of a phytosterol mixture, 2-3 grams per day of total phytosterols (not specifically isolated beta-sitosterol); the effect on prostate symptoms appears gradually and requires at least 8-12 weeks for clinical assessment.
Generally very well tolerated at the usual supplemental and dietary doses; the adverse effects described are rare and mild (mild digestive discomfort); the most important clinical consideration is sitosterolemia, a very rare genetic disease with abnormal intestinal hyperabsorption of phytosterols that produces high plasma levels and premature cardiovascular, hematological, and joint manifestations; in these (extremely rare) people phytosterols are contraindicated, but for the general population they do not represent a significant risk; people who take lipid-lowering drugs (statins, ezetimibe) can combine them with dietary phytosterols for modest additive effects; people being treated for benign prostatic hyperplasia with pharmacological alpha-blockers can combine them with beta-sitosterol under medical supervision; in pregnancy and breastfeeding the specific data as a supplement are limited, although the usual dietary intake is perfectly safe; commercial fortified products are an accessible way to reach effective doses in people with mild to moderate dyslipidemia who prefer dietary interventions before pharmacological ones.
Information, not medical advice. Scientific evidence reflects the quality of the studies.